A Global Effort to Bring Cell Based Therapies to PD Patients
Reprogrammed cells relieve Parkinson’s symptoms in trials Japanese researchers report promising results from an experimental therapy for Parkinson’s disease that involves implanting neurons made from ‘reprogrammed’ stem cells into the brain. A trial conducted in monkeys with a version of…
Read MoreLorenz Studer Awarded the 2017 Ogawa-Yamanaka Stem Cell Prize Lorenz P. Studer, MD, was announced today as the winner of the 2017 Ogawa-Yamanaka Stem Cell Prize by the Gladstone Institutes. Studer is the director of the Center for Stem Cell…
Read MoreTrials of embryonic stem cells to launch in China Jason Lee/Reuters In the next few months, surgeons in the Chinese city of Zhengzhou will carefully drill through the skulls of people with Parkinson’s disease and inject 4 million immature neurons…
Read MoreCongratulations to GForce-PD member Malin Parmar on being a elected into the 2016 class of NYSCF Robertson Investigators NYSCF Announces the Six Members of the 2016 Class of NYSCF – Robertson Investigators NYSCF announced the 2016 class of NYSCF –…
Read MoreStem cell researcher from Lund University receives the Fernström Prize Is it possible to convert a patient’s own skin cells into functioning nerve cells? Or insert
Read MoreBoom in unproven cell therapies intensifies regulatory debate Steve Gschmeissner/SPL Thomas Albini met his first patient blinded by a stem-cell ‘treatment’ last year. The elderly woman, who had macular degeneration, thought she was paying to participate in a clinical trial…
Read MoreA cautious note on the so called “Stem Cell Clinics” in the US. Please note that none offer treatments that were tested in clinical trials http://www.cell.com/cell-stem-cell/fulltext/S1934-5909(16)30157-6
Read MoreAnother way to dial back stem cell hype (but not hope): Put a dollar figure on it In an effort to reign in the hype surrounding stem cell research that has led to a proliferation of unapproved and potentially dangerous…
Read MoreStemCells, Inc. Announces Termination of Phase II Pathway Study Following Review of Data NEWARK, Calif., May 31, 2016 (GLOBE NEWSWIRE) — StemCells, Inc. (NASDAQ: STEM) (the “Company”) today announced its decision to terminate the Company’s Phase II Pathway Study in…
Read Morehttps://www.yahoo.com/news/national-stem-cell-foundation-michael-j-fox-foundation-140000914.html
Read More